Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The biliary tract cancers market was valued at USD 609.10 Billion in 2025 and is expected to grow at a CAGR of 6.10%, reaching USD 1101.14 Billion by 2035. The market growth is driven by the increasing need for effective treatments, including targeted therapies, immunotherapies, and chemotherapy. The development of precision medicine, biomarker-based patient selection, and novel drug candidates is expected to expand treatment options, improve clinical outcomes, and support market growth during the forecast period.
Compound Annual Growth Rate
6.1%
Value in USD Billion
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Biliary tract cancers are a group of malignancies affecting the bile ducts, gallbladder, and ampulla of Vater. These cancers often present with nonspecific symptoms and are frequently diagnosed at advanced stages, creating challenges for timely detection and effective treatment. Disease progression, limited early detection, and variable treatment outcomes contribute to the clinical burden. The market is shaped by the rising need for effective diagnostic and therapeutic approaches, including surgery, chemotherapy, targeted therapies, and immunotherapy. Advances in molecular profiling and biomarker identification are supporting more personalized treatment strategies. The market is poised to grow at a CAGR of 6.10% during the forecast period of 2026-2035. Ongoing clinical research, new drug development, and regulatory approvals are expanding therapeutic options, while high treatment costs, late diagnosis, and limited treatment efficacy in advanced disease remain key challenges.
|
Analysis Type |
Factors |
Example |
|
Market Drivers |
Growing Adoption of Combination Immunotherapy |
AstraZeneca's durvalumab and chemotherapy combination received approval in India in February 2023 after the TOPAZ-1 trial showed survival benefits in advanced biliary tract cancer. |
|
Market Restraints |
Aggressive Disease Progression and Therapeutic Limitations |
Late diagnosis, restricted eligibility for curative surgery, and treatment-related side effects complicate patient care and limit the effectiveness of available treatment approaches. |
|
Market Opportunities |
Development of Dual-Targeted Cancer Therapies |
In October 2026, a collaboration involving Akeso, Summit Therapeutics, and ECOG-ACRIN advanced plans to investigate ivonescimab alongside chemotherapy for advanced biliary tract cancer. |
The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.
Advancements in Immunotherapy Strengthen the Market Value
The increasing adoption of immunotherapy combined with chemotherapy is supporting the expansion of the market by improving treatment outcomes for patients with advanced disease. These combination therapies offer additional options for patients with limited treatment alternatives and poor prognoses. For instance, in February 2023, AstraZeneca announced that India's Central Drugs Standard Control Organization (CDSCO) had approved durvalumab in combination with chemotherapy for locally advanced or metastatic biliary tract cancer. The TOPAZ-1 trial demonstrated improved overall survival, supporting demand for advanced treatment options.
Poor Prognosis and Limited Treatment Options Challenge the Market Expansion
The frequent diagnosis of biliary tract cancer at an advanced stage, combined with its aggressive nature, presents a significant challenge to market growth. Limited opportunities for curative surgery and the need for more effective treatments complicate disease management. Treatment-related adverse reactions and the need for careful patient monitoring can also increase the complexity of care. These factors may restrict treatment effectiveness and complicate the broader adoption of newer therapies across patient populations.
Advancing Bispecific Antibody Therapies Could Expand the Market Landscape
The development of innovative immunotherapies creates potential for improved treatment outcomes and broader therapeutic options for patients with advanced biliary tract cancer. Therapies that simultaneously target multiple cancer-related pathways may offer advantages over existing treatment approaches. For instance, in October 2026, Akeso announced a collaboration involving Summit Therapeutics and the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab with chemotherapy in a Phase II/III trial for first-line treatment of advanced biliary tract cancer. This clinical development could support future treatment innovation and market expansion, subject to trial results and regulatory approval.
Some notable trends in the market include personalized medicine, genomic profiling, and the development of targeted combination therapies.
Increasing Adoption of Precision Medicine Is Likely to Support Market Growth
Precision medicine is gaining importance in biliary tract cancer treatment as genomic profiling helps identify tumor-specific targets and guide therapy selection. This approach may improve treatment personalization and expand the role of targeted therapies alongside established treatment regimens. For instance, in January 2025, University College London (UCL) announced the opening of the SAFIR-ABC10 trial, which uses genetic profiling to match patients with biliary tract cancer to selected anticancer therapies. These advances could support more individualized treatment strategies and contribute to market growth.
Intravenous Administration Is Expected to Lead the Market by Route of Administration
The market is segmented by route of administration into oral and intravenous formulations. The intravenous segment is expected to lead because several established treatment regimens for advanced biliary tract cancer rely on infused chemotherapy and immunotherapy, enabling the administration of combination treatments under clinical supervision. For instance, in October 2023, Merck announced that the US Food and Drug Administration (FDA) had approved pembrolizumab in combination with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer. The regimen is administered through intravenous infusion, supporting demand for this route.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The regions included in the report are the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to remain a leading market, supported by clinical research activity, established oncology infrastructure, and the development of innovative treatment options. For instance, in October 2026, the ECOG-ACRIN Cancer Research Group announced a US Phase II/III trial evaluating ivonescimab with chemotherapy against standard chemoimmunotherapy for advanced biliary tract cancer. This research activity could strengthen treatment development and support market growth in the United States.
The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by leading players. The major companies in the market are as follows:
Incyte Corporation is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies for unmet medical needs. Its product, Pemazyre (pemigatinib), is a selective fibroblast growth factor receptor (FGFR) inhibitor approved for previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The company contributes to the market through targeted treatment development.
Servier Pharmaceuticals LLC is involved in the market through TIBSOVO (ivosidenib), a targeted therapy for adults with previously treated, advanced cholangiocarcinoma harboring an isocitrate dehydrogenase-1 (IDH1) mutation. The oral treatment is designed to slow disease progression by targeting the specific mutation, providing a treatment option for eligible patients whose cancer has spread.
Taiho Pharmaceutical Co., Ltd. is a pharmaceutical company involved in the biliary tract cancer market through LYTGOBI (futibatinib), an oral, selective, irreversible FGFR inhibitor. In June 2023, the company received approval in Japan to manufacture and market LYTGOBI for unresectable biliary tract cancer with FGFR2 gene fusions that progressed after chemotherapy. The product expands targeted treatment options for eligible patients.
Merck & Co., Inc. is involved in the biliary tract cancer market through KEYTRUDA (pembrolizumab), an immunotherapy used in combination with gemcitabine and cisplatin to treat patients with locally advanced unresectable or metastatic biliary tract cancer. The treatment combines PD-1 inhibition with chemotherapy and has demonstrated an overall survival benefit compared with chemotherapy alone in clinical trials.
Other key players in the market include F. Hoffmann-La Roche Ltd. and AstraZeneca PLC.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
The market is influenced by ongoing advances in cancer treatment, increasing understanding of tumor biology, and the development of therapies targeting specific molecular pathways. Growing emphasis on personalized treatment strategies and improved clinical outcomes supports demand for diverse pharmacological approaches to biliary tract cancers.
Market Breakup by Route of Administration
Treatment delivery preferences are shaped by disease stage, patient condition, therapeutic requirements, and treatment protocols. Advances in oncology care and efforts to improve treatment adherence, clinical effectiveness, and patient convenience influence the use of different administration approaches in biliary tract cancer management.
Market Breakup by Distribution Channel
The distribution landscape is shaped by the need for reliable access to oncology medicines, specialized handling of certain therapies, and coordination among healthcare providers and suppliers. Hospital-based treatment, prescription fulfillment, and the growing use of digital healthcare services influence medicine procurement and availability.
Market Breakup by End User
Demand across healthcare settings is influenced by the complexity of biliary tract cancer diagnosis and treatment, the need for multidisciplinary oncology teams, and access to specialized diagnostic and therapeutic services. Continued improvements in cancer care infrastructure and supportive services also shape treatment delivery and patient management.
Market Breakup by Country
The market reflects differences in cancer incidence, healthcare infrastructure, reimbursement policies, access to innovative oncology medicines, and national treatment guidelines. Research investment, regulatory frameworks, and the availability of specialized cancer care services further influence the adoption of biliary tract cancer therapies across individual markets.
This report is developed using a robust mixed-methods research approach combining primary and secondary research to assess the biliary tract cancers market across eight major markets.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.